Floatz logo

GELDANAMYCIN, 17-DEMETHOXY-17-(2-PROPENYLAMINO)-

Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
81/ 100

Competitive context

52 Active assets in the Anaplastic Large Cell Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Seagen Inc.
Phase 4BBB
Crizotinib
Pfizer
Phase 4BBB
Inno-206
City of Hope Medical Center
Phase 4BBB
ETOPOSIDE
City of Hope Medical Center
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB

View all 50 →

Same molecule, other indications

GELDANAMYCIN, 17-DEMETHOXY-17-(2-PROPENYLAMINO)- is also rated in:

prostate cancerDormant
B
Indicative ·
59 / 100
View asset →
Hodgkins lymphomaDormant
B
Indicative ·
59 / 100
View asset →
mantle cell lymphomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →